Clinical stage biotechnology company ProMIS Neurosciences Inc (Nasdaq:PMN) on Friday announced the initiation of a Phase 1b clinical trial evaluating PMN310, its lead therapeutic candidate, in Alzheimer's disease (AD).

PMN310 is designed to target toxic oligomers of amyloid-beta while minimising the risk of amyloid-related imaging abnormalities (ARIA), a side effect associated with some existing therapies.

The Phase 1b trial will assess the safety, tolerability and pharmacokinetics of PMN310 in approximately 100 patients with mild cognitive impairment due to AD or early AD. The study will also evaluate key biomarkers and clinical measures of efficacy to gather data on PMN310's therapeutic potential.

Results from the recently completed Phase 1a study demonstrated a generally favourable safety and tolerability profile of PMN310 in healthy volunteers.